

Datasheet: MCA6104

BATCH NUMBER 154399

Description:	HUMAN ANTI INTEGRIN ALPHA 4 (NATALIZUMAB BIOSIMILAR)
Specificity:	INTEGRIN ALPHA 4
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	Natalizumab
Isotype:	IgG4
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Human IgG4 (kappa) antibody - liquid
Preparation	Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.02% Proclin 300
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	RAMOS cell line
Specificity	Human Anti-Integrin Alpha 4 Antibody is a research grade biosimilar of the monoclonal

antibody drug natalizumab. It is a recombinant human IgG4 kappa antibody with variable regions from the therapeutic antibody natalizumab.

Human Anti-Integrin Alpha 4 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-natalizumab antibodies, for example [HCA248](#) and [HCA249P](#). It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-natalizumab antibody in IgG1 format as reference standard, for example [HCA249](#).

Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn's disease. Natalizumab is also being evaluated for potential clinical use in the treatment of B-cell malignancies. This therapeutic antibody, directed against alpha-4 integrin (CD49d), binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.

This product is NOT FOR THERAPEUTIC USE.

[View a summary of supporting anti-natalizumab antibody products](#)

Purity	>98% by SDS PAGE
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #20463 available at: https://www.bio-rad-antibodies.com/SDS/MCA6104 20463
Licensed Use	For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

'M373152:200827'

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

Printed on 01 Mar 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)